Man and flame

The Lung Cancer Immunotherapy Race Heats Up!

Immunotherapy as an oncology treatment paradigm really came of age in 2014, with the first FDA approvals of anti-PD-1/PD-L1 therapies in advanced melanoma. Developments in the field look like they are not slowing down in 2015, with the race on for approval in the much larger lung cancer patient population.

High jump

FDA Drug Approvals Reach New Heights

The US FDA approved 41 novel new medicines in 2014, the highest number of approvals for 18 years. The list covered a wide variety of disease indications and included both interesting anticancer and antidiabetic agents, and notably 15 orphan drugs. We review the big hitters that made the list, and why some pricey agents are… Read more »


Cancer Evolution: Naturally Selecting Drug Resistance?

Darwin’s theory of natural selection was published in 1859, explaining how nature selects certain advantageous physical attributes (or phenotypes) to pass on to their offspring, so that they can better survive in their environment. Now over 150 years later, the theory is becoming a talking point in oncology, with natural selection within tumors helping to… Read more »

baking resize 2

Combination Therapies Mix Things Up at EORTC

Crown Bioscience recently attended the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. As well as manning a popular booth and presenting four scientific posters, we also reviewed the best of the drug development research on display. A particularly hot topic at this year’s conference was combination therapies.